Literature DB >> 18162445

Truncation of MBD4 predisposes to reciprocal chromosomal translocations and alters the response to therapeutic agents in colon cancer cells.

Wael M Abdel-Rahman1, Sakari Knuutila, Päivi Peltomäki, David J Harrison, Scott A Bader.   

Abstract

We previously identified a novel genomic instability phenotype of multiple reciprocal chromosomal translocations in a MLH1-defective, microsatellite unstable (MSI) colon cancer cell line (HCA7) and, further, showed that it was unlikely to be directly caused by the mismatch repair (MMR) defect in this cell line. To gain insight into the molecular basis to this novel translocation phenotype, we examined coding and splice-site nucleotide repeat tracts in DNA repair genes for mutations by direct sequencing together with RT-PCR expression analysis of the associated transcript. The material was a selected panel of 8 MSI cell lines including HCA7. A strong candidate identified through this approach was MBD4 as it showed a homozygous truncating mutation associated with substantial loss of the transcript in HCA7 not seen in the other lines. In previous published studies, heterozygous MBD4 mutations were observed in up to 89% of sporadic MSI microdissected colon tumor foci. Using MFISH, we show that over-expression of the truncated MBD4 (+MBD4(tru)) in DLD1, a MSH6 defective, MSI human colon carcinoma cell line predisposed these cells to acquire structural chromosomal rearrangements including multiple reciprocal translocations after irradiation, reminiscent of those seen in HCA7. We also show that over-expression of MBD4(tru) in DLD1 alters the colony survival after exposure to cisplatin or etoposide. These data suggest a wide role for MBD4 in DNA damage response and maintaining chromosomal stability.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18162445     DOI: 10.1016/j.dnarep.2007.11.009

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  10 in total

Review 1.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

Review 2.  Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials.

Authors:  Yuan Cheng; Cai He; Manni Wang; Xuelei Ma; Fei Mo; Shengyong Yang; Junhong Han; Xiawei Wei
Journal:  Signal Transduct Target Ther       Date:  2019-12-17

3.  Analysis of microsatellite instability in medulloblastoma.

Authors:  Marta Viana-Pereira; Inês Almeida; Sónia Sousa; Bethânia Mahler-Araújo; Raquel Seruca; José Pimentel; Rui Manuel Reis
Journal:  Neuro Oncol       Date:  2009-01-29       Impact factor: 12.300

4.  Genomic instability and carcinogenesis: an update.

Authors:  Wael M Abdel-Rahman
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

Review 5.  Uracil in DNA and its processing by different DNA glycosylases.

Authors:  Torkild Visnes; Berit Doseth; Henrik Sahlin Pettersen; Lars Hagen; Mirta M L Sousa; Mansour Akbari; Marit Otterlei; Bodil Kavli; Geir Slupphaug; Hans E Krokan
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2009-03-12       Impact factor: 6.237

6.  WITHDRAWN: Restoration of transforming growth factor-beta receptor II expression in colon cancer cells with microsatellite instability increases metastatic potential in vivo.

Authors:  Xiao-Qiong Liu; Ashwani Rajput; Liying Geng; Melanie Ongchin; Anathbandhu Chaudhuri; Jing Wang
Journal:  J Biol Chem       Date:  2011-03-17       Impact factor: 5.157

7.  Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 status.

Authors:  Satoshi Suzuki; Moriya Iwaizumi; Stephanie Tseng-Rogenski; Yasushi Hamaya; Hiroaki Miyajima; Shigeru Kanaoka; Ken Sugimoto; John M Carethers
Journal:  Cancer Biol Ther       Date:  2016-04-26       Impact factor: 4.742

8.  Apoptosis and DNA methylation.

Authors:  Huan X Meng; James A Hackett; Colm Nestor; Donncha S Dunican; Monika Madej; James P Reddington; Sari Pennings; David J Harrison; Richard R Meehan
Journal:  Cancers (Basel)       Date:  2011-04-01       Impact factor: 6.639

9.  Involvement of MBD4 inactivation in mismatch repair-deficient tumorigenesis.

Authors:  Rossella Tricarico; Salvatore Cortellino; Antonio Riccio; Shantie Jagmohan-Changur; Heleen Van der Klift; Juul Wijnen; David Turner; Andrea Ventura; Valentina Rovella; Antonio Percesepe; Emanuela Lucci-Cordisco; Paolo Radice; Lucio Bertario; Monica Pedroni; Maurizio Ponz de Leon; Pietro Mancuso; Karthik Devarajan; Kathy Q Cai; Andres J P Klein-Szanto; Giovanni Neri; Pål Møller; Alessandra Viel; Maurizio Genuardi; Riccardo Fodde; Alfonso Bellacosa
Journal:  Oncotarget       Date:  2015-12-15

10.  MBD4 frameshift mutation caused by DNA mismatch repair deficiency enhances cytotoxicity by trifluridine, an active antitumor agent of TAS-102, in colorectal cancer cells.

Authors:  Satoshi Suzuki; Moriya Iwaizumi; Hidetaka Yamada; Tomohiro Sugiyama; Yasushi Hamaya; Takahisa Furuta; Shigeru Kanaoka; Haruhiko Sugimura; Hiroaki Miyajima; Satoshi Osawa; John M Carethers; Ken Sugimoto
Journal:  Oncotarget       Date:  2017-11-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.